Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 2
1993 3
1994 4
1995 3
1996 5
1997 1
1998 4
1999 3
2000 8
2001 5
2002 7
2003 3
2004 6
2005 2
2006 6
2007 4
2008 13
2009 10
2010 10
2011 8
2012 8
2013 4
2014 3
2015 6
2016 1
2018 1
2019 4
2020 3
2021 4
2022 6
2023 10
2024 4
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for piketty c
Search for Picketty C instead (3 results)
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Ständer S; OLYMPIA 2 Investigators. Kwatra SG, et al. Among authors: piketty c. N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333. N Engl J Med. 2023. PMID: 37888917 Clinical Trial.
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.
Silverberg JI, Wollenberg A, Reich A, Thaçi D, Legat FJ, Papp KA, Stein Gold L, Bouaziz JD, Pink AE, Carrascosa JM, Rewerska B, Szepietowski JC, Krasowska D, Havlíčková B, Kalowska M, Magnolo N, Pauser S, Nami N, Sauder MB, Jain V, Padlewska K, Cheong SY, Fleuranceau Morel P, Ulianov L, Piketty C; ARCADIA 1 and ARCADIA 2 Study Investigators. Silverberg JI, et al. Among authors: piketty c. Lancet. 2024 Aug 3;404(10451):445-460. doi: 10.1016/S0140-6736(24)01203-0. Epub 2024 Jul 24. Lancet. 2024. PMID: 39067461 Clinical Trial.
Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab.
Tsoi LC, Hacini-Rachinel F, Fogel P, Rousseau F, Xing X, Patrick MT, Billi AC, Berthier CC, Kahlenberg JM, Lazzari A, Wiegmann H, Ständer S, Piketty C, Julia V, Krishnaswamy JK, Gudjonsson JE. Tsoi LC, et al. Among authors: piketty c. J Allergy Clin Immunol. 2022 Apr;149(4):1329-1339. doi: 10.1016/j.jaci.2021.10.004. Epub 2021 Nov 29. J Allergy Clin Immunol. 2022. PMID: 34857395 Free PMC article.
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.
Silverberg JI, Pinter A, Pulka G, Poulin Y, Bouaziz JD, Wollenberg A, Murrell DF, Alexis A, Lindsey L, Ahmad F, Piketty C, Clucas A. Silverberg JI, et al. Among authors: piketty c. J Allergy Clin Immunol. 2020 Jan;145(1):173-182. doi: 10.1016/j.jaci.2019.08.013. Epub 2019 Aug 23. J Allergy Clin Immunol. 2020. PMID: 31449914 Free article. Clinical Trial.
Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumab.
Ma F, Gharaee-Kermani M, Tsoi LC, Plazyo O, Chaskar P, Harms P, Patrick MT, Xing X, Hile G, Piketty C, Lazzari A, Van Delm W, Maverakis E, Nakamura M, Modlin RL, Kahlenberg JM, Billi AC, Julia V, Krishnaswamy JK, Gudjonsson JE. Ma F, et al. Among authors: piketty c. J Allergy Clin Immunol. 2024 Jan;153(1):146-160. doi: 10.1016/j.jaci.2023.07.005. Epub 2023 Jul 26. J Allergy Clin Immunol. 2024. PMID: 37506977 Free PMC article.
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.
Ständer S, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Metz M, Tsianakas A, Pink A, Fage S, Micali G, Weisshaar E, Sundaram H, Metelitsa A, Augustin M, Wollenberg A, Homey B, Fargnoli MC, Sofen H, Korman NJ, Skov L, Chen X, Jabbar-Lopez ZK, Piketty C, Kwatra SG; OLYMPIA 1 Investigators. Ständer S, et al. Among authors: piketty c. JAMA Dermatol. 2025 Feb 1;161(2):147-156. doi: 10.1001/jamadermatol.2024.4796. JAMA Dermatol. 2025. PMID: 39602139 Clinical Trial.
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
Ständer S, Yosipovitch G, Legat FJ, Lacour JP, Paul C, Narbutt J, Bieber T, Misery L, Wollenberg A, Reich A, Ahmad F, Piketty C. Ständer S, et al. Among authors: piketty c. N Engl J Med. 2020 Feb 20;382(8):706-716. doi: 10.1056/NEJMoa1908316. N Engl J Med. 2020. PMID: 32074418 Clinical Trial.
Prevalence of prurigo nodularis in the United States.
Kwatra SG, Puelles J, Tran O, Brouillette M, Lillehaugen T, Parthasarathy V, Deng J, Piketty C, Gabriel S. Kwatra SG, et al. Among authors: piketty c. JAAD Int. 2024 Mar 22;18:134-136. doi: 10.1016/j.jdin.2023.12.013. eCollection 2025 Feb. JAAD Int. 2024. PMID: 39719959 Free PMC article. No abstract available.
Nemolizumab Treatment Normalizes Dysregulated Microbiome in Lesional Prurigo Nodularis.
Zhou R, Chaskar P, Patrick MT, Wang K, Piketty C, Julia V, Gudjonsson JE, Krishnaswamy JK, Tsoi LC. Zhou R, et al. Among authors: piketty c. J Invest Dermatol. 2025 Jun 25:S0022-202X(25)02231-6. doi: 10.1016/j.jid.2025.06.1575. Online ahead of print. J Invest Dermatol. 2025. PMID: 40571154 Free article. No abstract available.
156 results